Skip to content
Screener

Madrigal Pharmaceuticals, Inc. MDGL Balance Sheet Statement

Q2 '26Q1 '26Q4 '25Q3 '25Q2 '25
$292.88M+53.2%$232.19M+23.1%$203.78M+94.0%$300.69M+26.5%$191.19M-61.7%
$546.03M-10.6%$585.74M-11.2%$784.87M-5.0%$814.06M+6.3%$610.83M+8.5%
$192.31M+143%$187.36M+205%$134.48M+150%$113.29M+272%$79.23M+1,048%
$99.39M+56.5%$112.07M+103%$74.84M+120%$69.32M+695%$63.5M+798%
$1.2B+19.5%$1.18B+19.7%$1.25B+20.6%$1.35B+26.6%$1B-8.1%
$11.59M+618%$8.04M+323%$1.5M-31.6%$2.91M+28.4%$1.62M-4.7%
$7.19M+58.0%$7.28M+57.0%$7.38M+56.1%$7.48M+55.2%$4.55M-7.4%
$1.24B+22.6%$1.23B+23.1%$1.26B+20.9%$1.36B+26.9%$1.02B-7.7%
$34.51M-9.1%$60.8M+44.6%$48.88M+12.1%$44.94M-2.2%$37.98M+322%
$30.1M+159%$29.98M+158%$31.06M+155%$11.6M-9.1%
$374.2M+90.4%$338.26M+102%$310.29M+83.3%$391.41M+120%$196.5M+57.0%
$340.79M+188%$340.33M+188%$339.88M+189%$339.75M+190%$118.38M+1.5%
$346.72M+182%$345.61M+191%$346.61M+192%$345.32M+192%$122.9M+4.6%
$720.92M+126%$683.87M+139%$656.9M+128%$736.73M+149%$319.4M+31.6%
200M0.0%200M0.0%2K0.0%200M0.0%200M0.0%
-$2.24B-17.0%-$2.18B-16.5%-$2.09B-16.0%-$2.03B-16.6%-$1.92B-17.2%
$523.72M-24.7%$543.45M-23.5%$602.69M-20.1%$625.73M-19.5%$695.98M-18.8%
$1.24B+22.6%$1.23B+23.1%$1.26B+20.9%$1.36B+26.9%$1.02B-7.7%

FAQ

What are Madrigal Pharmaceuticals, Inc.'s total assets?
Madrigal Pharmaceuticals, Inc. (MDGL) holds $1.2B in total assets, up 22.6% year over year.
How much debt does Madrigal Pharmaceuticals, Inc. have?
Madrigal Pharmaceuticals, Inc. carries $377.9M in total debt against $523.7M of shareholders' equity, a debt-to-equity ratio of 0.72.
How much cash does Madrigal Pharmaceuticals, Inc. have?
Madrigal Pharmaceuticals, Inc. holds $292.9M in cash and equivalents.
Can Madrigal Pharmaceuticals, Inc. cover its short-term obligations?
Its current ratio is 3.20 — current assets exceed current liabilities.
Where does Madrigal Pharmaceuticals, Inc.'s balance sheet data come from?
Every line is extracted from Madrigal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.